Organizing Committee
Norman Baylor
FDA
Steve Black
Cincinnati Children's Hospital Medical Center
Giuseppe Del Giudice
Novartis Vaccines & Diagnostics
William Egan
PharmaNet
Martin Friede
WHO
Nathalie Garçon
GSK Biologicals
Ian Gust
University of Melbourne
Paul-Henri Lambert
University of Geneva
Pieter Neels
Federal Agency for Medicines and Health
Products of Belgium
Emanuelle Trannoy
Sanofi Pasteur
Kathryn Zoon
NIH
Executive Committee
William Egan
PharmaNet
Paul-Henri Lambert
University of Geneva
Betty Dodet
Dodet Bioscience
Coordination : Dodet Bioscience - Lyon |
Objectives
- To review present knowledge on the mode of action of adjuvants;
- To consider how understanding the mode of action of adjuvants can help to address safety issues;
- To consider how progress in adjuvant science can assist vaccine design;
- To facilitate exchanges between experts from academia, industry and regulatory agencies.
Outcomes
- Conclusions and recommendations will be issued at the end of the meeting and published.
Who should attend?
- This event will be of interest to experts working in the field of human vaccines, whether from the public or private sector or from regulatory agencies.
|
